Effects of nuclear factor‑κB on the uptake of 131iodine and apoptosis of thyroid carcinoma cells

Chen,Fukun; Yin,Shuting; Zhu,Jialun; Jia,Li; Zhang,Huaping; Yang,Chuanzhou; Liu,Chao; Deng,Zhiyong

doi:10.3892/mmr.2018.8481

Effects of nuclear factor‑κB on the uptake of 131iodine and apoptosis of thyroid carcinoma cells

Authors:
- Fukun Chen
- Shuting Yin
- Jialun Zhu
- Li Jia
- Huaping Zhang
- Chuanzhou Yang
- Chao Liu
- Zhiyong Deng
View Affiliations

Affiliations: Department of Nuclear Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650118, P.R. China, Third Ward of The Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650101, P.R. China
Published online on: January 25, 2018 https://doi.org/10.3892/mmr.2018.8481
Pages: 4959-4964
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thyroid carcinoma is primarily treated by surgery combined with radioactive 131iodine (131I) treatment; however, certain patients exhibit resistance to 131I treatment. Previous research indicated that nuclear factor‑κB (NF‑κB) was associated with resistance to 131I in cancer cells. The present study aimed to investigate the effects of NF‑κB on 131I uptake and apoptosis in thyroid carcinoma cells. TPC‑1 and BCPAP cell lines were employed as research models in the present study, and the expression of NF‑κB was inhibited by RNA interference (RNAi). The ability of TPC‑1 and BCPAP cells to uptake 131I was measured and the cell viability was detected by an MTT assay. Finally, the expression of the apoptosis‑associated proteins X‑linked inhibitor of apoptosis (XIAP), cellular inhibitor of apoptosis protein 1 (cIAP1) and caspase‑3 in TCP‑1 and BCPAP cells was determined by western blotting. Western blotting results demonstrated that the expression levels of NF‑κB in TPC‑1 and BCPAP cells were successfully downregulated by RNAi (P<0.05), while analysis of 131I uptake revealed no significant alterations in the 131I uptake ability of cells following RNAi (P>0.05). MTT experiments demonstrated that the inhibition of NF‑κB expression in combination with radiation (131I treatment) led to a marked reduction in cell viability (P<0.05). Furthermore, western blot analysis revealed that the inhibition of NF‑κB expression downregulated the expression levels of XIAP and cIAP1 (P<0.05), while the expression levels of caspase‑3 were upregulated, indicating that the observed reduction in cell viability following NF‑κB inhibition may be due to an increased level of apoptosis. Although NF‑κB inhibition did not affect the 131I uptake of thyroid cancer cells, this inhibition may increase the apoptotic effects of radioactive 131I.

View Figures

View References

1	Pellegriti G, Frasca F, Regalbuto C, Squatrito S and Vigneri R: Worldwide increasing incidence of thyroid cancer: Update on epidemiology and risk factors. J Cancer Epidemiol. 2013:9652122013. View Article : Google Scholar : PubMed/NCBI
2	Londero SC, Krogdahl A, Bastholt L, Overgaard J, Trolle W, Pedersen HB, Bentzen J, Schytte S, Christiansen P and Godballe C; Danish Thyroid Cancer Group, : Papillary thyroid microcarcinoma in Denmark 1996–2008: A national study of epidemiology and clinical significance. Thyroid. 23:1159–1164. 2013. View Article : Google Scholar : PubMed/NCBI
3	Lin Y: Internal radiation therapy: A neglected aspect of nuclear medicine in the molecular era. J Biomed Res. 29:345–355. 2015.PubMed/NCBI
4	Pryma DA and Mandel SJ: Radioiodine therapy for thyroid cancer in the era of risk stratification and alternative targeted therapies. J Nucl Med. 55:1485–1491. 2014. View Article : Google Scholar : PubMed/NCBI
5	Lu L, Shan F, Li W and Lu H: Short-term side effects after radioiodine treatment in patients with differentiated thyroid cancer. Biomed Res Int. 2016:43767202016. View Article : Google Scholar : PubMed/NCBI
6	Hombach-Klonisch S, Natarajan S, Thanasupawat T, Medapati M, Pathak A, Ghavami S and Klonisch T: Mechanisms of therapeutic resistance in cancer (stem) cells with emphasis on thyroid cancer cells. Front Endocrinol (Lausanne). 5:372014.PubMed/NCBI
7	Sen R and Baltimore D: Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 46:705–716. 1986. View Article : Google Scholar : PubMed/NCBI
8	Sen R and Baltimore D: Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell. 47:921–928. 1986. View Article : Google Scholar : PubMed/NCBI
9	Vallabhapurapu S and Karin M: Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 27:693–733. 2009. View Article : Google Scholar : PubMed/NCBI
10	Hayden MS and Ghosh S: NF-κB, the first quarter-century: Remarkable progress and outstanding questions. Genes Dev. 26:203–234. 2012. View Article : Google Scholar : PubMed/NCBI
11	Zhang H and Sun SC: NF-kappaB in inflammation and renal diseases. Cell Biosci. 5:632015. View Article : Google Scholar : PubMed/NCBI
12	Wertz IE and Dixit VM: Signaling to NF-kappaB: Regulation by ubiquitination. Cold Spring Harb Perspect Biol. 2:a0033502010. View Article : Google Scholar : PubMed/NCBI
13	Oeckinghaus A, Hayden MS and Ghosh S: Crosstalk in NF-κB signaling pathways. Nat Immunol. 12:695–708. 2011. View Article : Google Scholar : PubMed/NCBI
14	Pozdeyev N, Berlinberg A, Zhou Q, Wuensch K, Shibata H, Wood WM and Haugen BR: Targeting the NF-κB Pathway as a combination therapy for advanced thyroid cancer. PLos One. 10:e01349012015. View Article : Google Scholar : PubMed/NCBI
15	Li F and Sethi G: Targeting transcription factor NF-kappa B to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta. 1805:167–180. 2010.PubMed/NCBI
16	Lin Y, Bai L, Chen WJ and Xu SL: The NF-kappa B activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Tar. 14:45–55. 2010. View Article : Google Scholar
17	Bauerle KT, Schweppe RE and Haugen BR: Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion. Mol Cancer. 9:1172010. View Article : Google Scholar : PubMed/NCBI
18	Phan T, Yu XM, Kunnimalaiyaan M and Chen H: Antiproliferative effect of chrysin on anaplastic thyroid cancer. J Surg Res. 170:84–88. 2011. View Article : Google Scholar : PubMed/NCBI
19	Letovsky SI, Cottingham RW, Porter CJ and Li PW: GDB: The human genome database. Nucleic Acids Res. 26:94–99. 1998. View Article : Google Scholar : PubMed/NCBI
20	Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K and Madden TL: BLAST+: Architecture and applications. BMC Bioinformatics. 10:4212009. View Article : Google Scholar : PubMed/NCBI
21	Flux GD, Haq M, Chittenden SJ, Buckley S, Hindorf C, Newbold K and Harmer CL: A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 37:270–275. 2010. View Article : Google Scholar : PubMed/NCBI
22	Chen GF, Xu SH, Renko K and Derwahl M: Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J Clin Endocr Metab. 97:E510–E520. 2012. View Article : Google Scholar : PubMed/NCBI
23	Verburg FA, Stokkel MP, Düren C, Verkooijen RB, Mäder U, van Isselt JW, Marlowe RJ, Smit JW, Reiners C and Luster M: No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 37:276–283. 2010. View Article : Google Scholar : PubMed/NCBI
24	Kim WG, Ryu JS, Kim EY, Lee JH, Baek JH, Yoon JH, Hong SJ, Kim ES, Kim TY, Kim WB and Shong YK: Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan. J Clin Endocr Metab. 95:1169–1173. 2010. View Article : Google Scholar : PubMed/NCBI
25	Pacifico F and Leonardi A: Role of NF-kappa B in thyroid cancer. Mol Cell Endocrinol. 321:29–35. 2010. View Article : Google Scholar : PubMed/NCBI
26	Lampiasi N, Azzolina A, Umezawa K, Montalto G, McCubrey JA and Cervello M: The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. Cancer Lett. 322:35–44. 2012. View Article : Google Scholar : PubMed/NCBI
27	Galbán S and Duckett CS: XIAP as a ubiquitin ligase in cellular signaling. Cell Death Differ. 17:54–60. 2010. View Article : Google Scholar : PubMed/NCBI
28	Jiang CY and Lin X: Regulation of NF-κB by the CARD proteins. Immunol Rev. 246:141–153. 2012. View Article : Google Scholar : PubMed/NCBI
29	Go HS, Seo JE, Kim KC, Han SM, Kim P, Kang YS, Han SH, Shin CY and Ko KH: Valproic acid inhibits neural progenitor cell death by activation of NF-κB signaling pathway and up-regulation of Bcl-XL. J Biomed Sci. 18:482011. View Article : Google Scholar : PubMed/NCBI
30	Gyrd-Hansen M and Meier P: IAPs: From caspase inhibitors to modulators of NF-kappa B, inflammation and cancer. Nat Rev Cancer. 10:561–574. 2010. View Article : Google Scholar : PubMed/NCBI
31	Bratton SB and Salvesen GS: Regulation of the Apaf-1-caspase-9 apoptosome. J Cell Sci. 123:3209–3214. 2010. View Article : Google Scholar : PubMed/NCBI
32	Altieri DC: Survivin and IAP proteins in cell-death mechanisms. Biochem J. 430:199–205. 2010. View Article : Google Scholar : PubMed/NCBI
33	Zhang SN, Deng BP, Zhang YY and Jiang NY: Expression of miR-100 and RBSP3 in FTC-133 cells after exposure to I-131. Nucl Med Commun. 35:932–938. 2014. View Article : Google Scholar : PubMed/NCBI
34	Duronio RJ and Xiong Y: Signaling pathways that control cell proliferation. Cold Spring Harb Perspect Biol. 5:a0089042013. View Article : Google Scholar : PubMed/NCBI
35	Liu M, Sakamaki T, Casimiro MC, Willmarth NE, Quong AA, Ju X, Ojeifo J, Jiao X, Yeow WS, Katiyar S, et al: The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Res. 70:10464–10473. 2010. View Article : Google Scholar : PubMed/NCBI
36	Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C and Strauss M: NF-kappaB function in growth control: Regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol. 19:2690–2698. 1999. View Article : Google Scholar : PubMed/NCBI
37	Li XY, Abdel-Mageed AB, Mondal D and Kandil E: The nuclear factor Kappa-B signaling pathway as a therapeutic target against thyroid cancers. Thyroid. 23:209–218. 2013. View Article : Google Scholar : PubMed/NCBI